Floatz logo

PSMA-HBED-CC ALF-18

18F-PSMA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

514 Active assets in the 18F-PSMA cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

PSMA-HBED-CC ALF-18 is also rated in:

male reproductive system neoplasmDormant
B
Indicative ·
57 / 100
View asset →
neoplasmDormant
B
Indicative ·
57 / 100
View asset →
male reproductive system disorderDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →